CAIX-targeted α therapy directed against hypoxic tumor cells in combination with immune checkpoint inhibitors in a syngeneic mouse tumor model
Overall, these results demonstrate first proof-of-concept of the potential of CAIX-TAT to treat hypoxic tumors by targeting CAIX-positive hypoxic tumor regions. CAIX-TAT combined with ICI was most effective in inhibiting tumor growth and prolonging survival of tumor-bearing mice. Future studies are required to investigate the radiobiological and immunological effects of CAIX-TAT, to guide optimization of this treatment in combination with ICI.
Authors
- Janneke D.M. Molkenboer‐Kuenen (ORCID: https://orcid.org/0009-0007-0879-5660)
- G Tamborino (ORCID: https://orcid.org/0000-0003-3832-3625)
- Daphne Lobeek (ORCID: https://orcid.org/0000-0003-1282-0826)
- Daan F. Boreel (ORCID: https://orcid.org/0000-0002-6025-1579)
- Sylvia T.M. Wenker
- Johan Bussink
- Sanne A.M. van Lith
- Simone C Kleinendorst
- Sandra Heskamp
- Gerben M. Franssen
- Mark W. Konijnenberg
- Hans Peters
Institutions
- Radboud University Nijmegen (NL)
- Catharina Ziekenhuis (NL)
- Radboud University Medical Center (NL)
- Radboud Institute for Molecular Life Sciences (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Theranostics
- Published
- 2026-02-11
- DOI
- https://doi.org/10.7150/thno.127288
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek